This company listing is no longer active
Gamida Cell Management
Management criteria checks 2/4
Gamida Cell's CEO is Abbey Jenkins, appointed in Sep 2022, has a tenure of 1.67 years. total yearly compensation is $1.36M, comprised of 41.8% salary and 58.2% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $9.89K. The average tenure of the management team and the board of directors is 2.9 years and 4.9 years respectively.
Key information
Abbey Jenkins
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 41.84% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Gamida Cell shares slide after stock offering
Sep 27Gamida appoints Emergent’s former head of vaccines as new CEO
Sep 19Gamida Cell Q2 2022 Earnings Preview
Aug 12Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel
Aug 01Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?
Feb 23
Gamida Cell: Recapping A Tough Year
Nov 02Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$62m |
| Dec 31 2023 | US$1m | US$571k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$93m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$707k | US$157k | -US$79m |
Compensation vs Market: Abbey's total compensation ($USD1.36M) is above average for companies of similar size in the US market ($USD661.07K).
Compensation vs Earnings: Abbey's compensation has increased whilst the company is unprofitable.
CEO
Abbey Jenkins (47 yo)
Ms. Abigail L. Jenkins, M.S. also known as Abbey, serves as a Director at XORTX Therapeutics Inc. since April 08, 2024. She is Independent Director of Aquestive Therapeutics, Inc. from April 1, 2024. She i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.7yrs | US$1.36m | 0.38% $ 9.9k | |
| Chief Financial Officer | 1yr | US$1.06m | no data | |
| Chief Medical Officer & Chief Scientific Officer | 6.8yrs | US$1.34m | 0.33% $ 8.7k | |
| Vice President of Marketing & Account Management | 3.3yrs | no data | no data | |
| Chief Human Resource Officer | 1.5yrs | no data | no data | |
| Senior Vice President Finance & Operations | no data | no data | no data | |
| Scientific Advisor & Consultant | 2.8yrs | no data | no data | |
| Senior Vice President of Global Operations & Manufacturing | 2.9yrs | no data | no data | |
| Chief of Staff | no data | no data | no data | |
| Senior Vice President of Market Access | 3.5yrs | no data | no data | |
| Head of Global Information Technology | no data | no data | no data |
Experienced Management: GMDA.Q's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.7yrs | US$1.36m | 0.38% $ 9.9k | |
| Independent Director | 7.8yrs | US$179.77k | 0.10% $ 2.7k | |
| Independent Director | 4.9yrs | US$213.10k | 0.12% $ 3.2k | |
| Director | 7.8yrs | US$865.34k | 0.89% $ 23.4k | |
| Independent Chairwoman | 4.9yrs | US$209.17k | 0.11% $ 2.8k | |
| Independent Director | 1.9yrs | US$161.86k | 0.070% $ 1.8k |
Experienced Board: GMDA.Q's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/26 19:17 |
| End of Day Share Price | 2024/05/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gamida Cell Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Cross | Alliance Global Partners |
| Matthew Luchini | BMO Capital Markets Equity Research |
| Jason Butler | Citizens JMP Securities, LLC |